CoronaryAtlas logo
CoronaryAtlas
Fibrin degradation products
Pathway / Coagulation & thrombus formation

Fibrin degradation products

protein

Products of plasmin-mediated fibrin degradation indicating active fibrinolysis in acute coronary thrombosis.

Pathway placement
Cascade stepCoagulation & thrombus formation
Confidencehigh
RationaleDirect marker of fibrinolytic activity and thrombus turnover.
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
85
C — confounder / Type-II
77
A — assay feasibility
68
E — evidence strength
33
T1DI (composite)
12
Specificity differential (R−C)+8.3
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)

Literature evidence(8)